Highlights

  • Cleo Diagnostics has commenced a staged Manufacturing and development program with Bio-Techne Corporation following completion of sample collection for its pivotal US clinical trial across 19 sites.
  • The program focuses on antibody production, assay optimisation, and test kit Manufacturing using Bio-Techne's Ella platform — the data generated will form the core evidence package for the planned FDA 510(k) submission.
  • COV shares were unchanged at A$0.625 on 28 April 2026 with 523,942 shares traded, while the company's Market Capitalisation stood at approximately A$85.53 million.

 

Cleo Diagnostics Limited (ASX:COV) closed at A$0.625 on 28 April 2026, unchanged from the prior session, with 523,942 shares traded. The company's Market Capitalisation at that price was approximately A$85.53 million, positioning Cleo as a small-cap ASX-listed medical diagnostics company at a pre-Revenue development stage. The flat share price response to the Manufacturing commencement announcement reflects the market's measured approach to milestone events in early-stage medical technology companies — acknowledging the progress without extrapolating prematurely to a commercial outcome.

For investors following Cleo Diagnostics, context is everything. The company is pursuing regulatory approval for a novel blood-based ovarian cancer diagnostic, a category of clinical need with enormous unmet Demand globally. The announcement that Manufacturing activities have commenced with Bio-Techne represents a transition from clinical trial execution to the laboratory and Manufacturing processes that directly feed an FDA regulatory submission. This is a meaningful step forward in a development pathway that has been carefully staged since the company's founding.

The Manufacturing Program: Staged and De-Risked

Cleo Diagnostics has adopted a staged Manufacturing and development framework with Bio-Techne Corporation (Nasdaq: TECH), a global life sciences company with extensive expertise in immunoassay development and commercial-scale Manufacturing. This approach builds on the company's established collaboration using Bio-Techne's proprietary Ella platform as the dedicated instrument for delivering Cleo's Pre-Surgical Ovarian Cancer Test.

The initial phase of the staged program is focused on the development and optimisation of critical assay components, with particular emphasis on antibody production and preparation across selected biomarkers within Cleo's proprietary panel. Antibody quality and consistency are foundational to any immunoassay-based diagnostic — they determine the specificity and sensitivity of the test across patient samples and Manufacturing batches. By investing in this foundational work now, Cleo is reducing the technical and Manufacturing risk that could otherwise emerge during full-scale kit production.

The company confirmed that its in-house validation of the Ella platform has demonstrated consistent delivery of Cleo's biomarker panel with high sensitivity, precision, and reproducibility. This internal validation work provides the technical foundation for scaling up Manufacturing with Bio-Techne, giving both parties confidence in the platform's ability to produce test kits that will meet the rigorous performance standards required for FDA analytical validation.

From Clinical Sample Collection to Analytical Validation

The Manufacturing program announcement follows Cleo's recently completed milestone of collecting all clinical samples for its pivotal US clinical trial across 19 trial sites, as reported in the company's 31 March 2026 ASX announcement. The completion of sample collection represents the end of the clinical recruitment phase of the trial and the beginning of the final execution phase — the analytical validation of test kits and the testing of those clinical samples to generate the efficacy data required for the FDA submission.

Analytical Validation is the critical regulatory bridge between Manufacturing test kits and using them to evaluate patient samples. It requires demonstrating that the test kits perform consistently and reproducibly within defined acceptance criteria before being used to analyse the clinical trial cohort. The FDA's 510(k) clearance pathway for medical devices requires robust analytical validation data as part of the substantial equivalence evidence package, and Cleo's staged Manufacturing approach is designed specifically to generate this data in a controlled and reproducible manner.

The CXCL10 Biomarker Advantage

At the core of Cleo's diagnostic platform is a novel patented biomarker, CXCL10, which is produced early and at high levels by ovarian cancers but is largely absent in non-malignant disease. This biological property — early and elevated expression in malignant ovarian pathology, with minimal expression in benign conditions — is precisely what a pre-surgical triage test requires. The ability to distinguish malignant from benign ovarian growths through a simple blood test could fundamentally alter the pre-surgical diagnostic pathway for women presenting with pelvic masses.

Ovarian cancer carries a particularly poor prognosis when diagnosed at late stages due to the absence of effective screening tools for the general population. The clinical unmet need for an accurate, early-stage detection test is significant — late-stage diagnoses dramatically reduce survivability, while early-stage detection enables curative surgical intervention. Cleo's platform, backed by more than 15 years of Research and Development at the Hudson Institute of Medical Research and validated in two prior clinical studies involving more than 500 patients, is positioned to address the pre-surgical component of this diagnostic gap.

Bio-Techne Partnership

Bio-Techne Corporation is a global life sciences company with Revenue exceeding US$1.2 billion in fiscal year 2025 and approximately 3,100 employees worldwide. Its selection as Cleo's preferred Manufacturing partner reflects the importance of working with a partner that has the scientific credibility, Manufacturing infrastructure, and regulatory experience to support both the development and commercial-scale production of a high-sensitivity immunoassay diagnostic. Bio-Techne's Ella platform has been independently validated in the scientific literature for high-sensitivity biomarker measurement, providing an additional layer of technical credibility for Cleo's FDA submission.

Path to FDA 510(k) Submission

The next steps outlined by Cleo Diagnostics provide a clear sequencing of activities leading to the FDA submission: completion of reagent and antibody production; manufacture of multiple production batches of test kits for use on the Ella platform; completion of analytical validation; testing of clinical trial samples using the validated test configuration; and analysis of clinical trial data to generate the evidence package for the 510(k) submission. Each step builds on the previous one in a logical and well-structured sequence that reflects a professional regulatory execution strategy.

Forward Outlook

Cleo Diagnostics enters its most operationally intensive regulatory phase with the Manufacturing program now underway and analytical validation as the next major activity milestone. The company's staged approach with Bio-Techne is designed to minimise the risk of Manufacturing failures that could delay the submission timeline, and the completion of clinical sample collection removes a major source of execution uncertainty. For investors, the key questions are the timeline to FDA 510(k) submission and, ultimately, the clinical performance data generated from the pivotal trial samples — the metrics that will determine the strength of the regulatory dossier Cleo presents to the FDA.